On the public citation graph
Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
0 signed · 115 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archopht.1995.01100020100038openalex-snapshot
Hypertension, Perfusion Pressure, and Primary Open-angle Glaucoma
inferredcites →https://doi.org/10.1001/archophthalmol.2011.2573openalex-snapshot
Diurnal and Nocturnal Variations in Aqueous Humor Dynamics of Patients With Ocular Hypertension Undergoing Medical Therapy
inferredcites →https://doi.org/10.1007/s10384-020-00748-xopenalex-snapshot
Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study
inferredcites →https://doi.org/10.1007/s12325-015-0260-yopenalex-snapshot
Evaluation of the Effect of Latanoprostene Bunod Ophthalmic Solution, 0.024% in Lowering Intraocular Pressure over 24 h in Healthy Japanese Subjects
inferredcites →https://doi.org/10.1007/s12325-016-0385-7openalex-snapshot
Long-term Safety and Efficacy of Latanoprostene Bunod 0.024% in Japanese Subjects with Open-Angle Glaucoma or Ocular Hypertension: The JUPITER Study
inferredcites →https://doi.org/10.1007/s40123-017-0094-6openalex-snapshot
A Review of Nitric Oxide for the Treatment of Glaucomatous Disease
inferredcites →https://doi.org/10.1016/0006-2952(91)90618-fopenalex-snapshot
Signal transduction mechanisms involving nitric oxide
inferredcites →https://doi.org/10.1016/j.ajo.2016.04.019openalex-snapshot
Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours
inferredcites →https://doi.org/10.1016/j.ajo.2016.05.012openalex-snapshot
Comparison of Latanoprostene Bunod 0.024% and Timolol Maleate 0.5% in Open-Angle Glaucoma or Ocular Hypertension: The LUNAR Study
inferredcites →https://doi.org/10.1016/j.ajo.2020.06.003openalex-snapshot
Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension
inferredcites →https://doi.org/10.1016/j.exer.2003.12.007openalex-snapshot
Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug
inferredcites →https://doi.org/10.1016/j.exer.2008.12.012openalex-snapshot
Uveoscleral outflow – A review
inferredcites →https://doi.org/10.1016/j.exer.2011.02.006openalex-snapshot
A dual acting compound with latanoprost amide and nitric oxide releasing properties, shows ocular hypotensive effects in rabbits and dogs
inferredcites →https://doi.org/10.1016/j.exer.2011.02.015openalex-snapshot
Effect of PF-04217329 a prodrug of a selective prostaglandin EP2 agonist on intraocular pressure in preclinical models of glaucoma
inferredcites →https://doi.org/10.1016/j.exer.2011.03.001openalex-snapshot
Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2α agonist, in preclinical models
inferredcites →https://doi.org/10.1016/j.exer.2013.09.008openalex-snapshot
Role of nitric oxide in optic nerve head blood flow regulation during an experimental increase in intraocular pressure in healthy humans
inferredcites →https://doi.org/10.1016/j.ophtha.2005.10.045openalex-snapshot
Comparison of the Effects of Latanoprost, Travoprost, and Bimatoprost on Circadian Intraocular Pressure in Patients with Glaucoma or Ocular Hypertension
inferredcites →https://doi.org/10.1016/j.ophtha.2016.01.019openalex-snapshot
Latanoprostene Bunod 0.024% versus Timolol Maleate 0.5% in Subjects with Open-Angle Glaucoma or Ocular Hypertension
inferredcites →https://doi.org/10.1016/j.preteyeres.2004.10.003openalex-snapshot
Changes in aqueous humor dynamics with age and glaucoma
inferredcites →https://doi.org/10.1016/s0165-6147(00)01499-1openalex-snapshot
The dual personality of NO
inferredcites →https://doi.org/10.1038/sj.bjp.0707434openalex-snapshot
Prostamides (prostaglandin‐ethanolamides) and their pharmacology
inferredcites →https://doi.org/10.1080/14656566.2017.1293654openalex-snapshot
Latanoprostene bunod ophthalmic solution 0.024% for IOP lowering in glaucoma and ocular hypertension
inferredcites →https://doi.org/10.1089/jop.2009.0098openalex-snapshot
Aqueous Humor Concentrations of Bimatoprost Free Acid, Bimatoprost and Travoprost Free Acid in Cataract Surgical Patients Administered Multiple Topical Ocular Doses of LUMIGAN ® or TRAVATAN ®
inferredcites →https://doi.org/10.1089/jop.2009.0120openalex-snapshot
A Novel Nitric Oxide Releasing Prostaglandin Analog, NCX 125, Reduces Intraocular Pressure in Rabbit, Dog, and Primate Models of Glaucoma
inferredcites →https://doi.org/10.1089/jop.2012.0186openalex-snapshot
Prostaglandin Analogs and Timolol-Fixed Versus Unfixed Combinations or Monotherapy for Open-Angle Glaucoma: A Systematic Review and Meta-Analysis
inferredcites →https://doi.org/10.1089/jop.2013.0179openalex-snapshot
Effects of Prostaglandin Analogues on Aqueous Humor Outflow Pathways
inferredcites →https://doi.org/10.1089/jop.2013.0222openalex-snapshot
Investigation of Ocular Events Associated with Taprenepag Isopropyl, a Topical EP2 Agonist in Development for Treatment of Glaucoma
inferredcites →https://doi.org/10.1089/jop.2016.0188openalex-snapshot
The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
inferredcites →https://doi.org/10.1093/nar/gkx1121openalex-snapshot
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
inferredcites →https://doi.org/10.1097/icu.0000000000000245openalex-snapshot
Vascular and autonomic dysregulation in primary open-angle glaucoma
inferredcites →https://doi.org/10.1097/ijg.0000000000000449openalex-snapshot
Ocular Hypotensive Effect of ONO-9054, an EP3/FP Receptor Agonist: Results of a Randomized, Placebo-controlled, Dose Escalation Study
inferredcites →https://doi.org/10.1097/ijg.0b013e3181666557openalex-snapshot
Efficacy and Tolerability of Prostaglandin Analogs
inferredcites →https://doi.org/10.1111/aos.12298openalex-snapshot
Ocular perfusion pressure in glaucoma
inferredcites →https://doi.org/10.1111/bph.13877openalex-snapshot
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Enzymes
inferredcites →https://doi.org/10.1111/bph.13878openalex-snapshot
THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein‐coupled receptors
inferredcites →https://doi.org/10.1111/bph.14328openalex-snapshot
Prostaglandin analogues and nitric oxide contribution in the treatment of ocular hypertension and glaucoma
inferredcites →https://doi.org/10.1111/j.1527-3466.2005.tb00168.xopenalex-snapshot
Bimatoprost: Mechanism of Ocular Surface Hyperemia Associated with Topical Therapy
inferredcites →https://doi.org/10.1111/j.1755-3768.2007.01167.xopenalex-snapshot
Endothelial dysfunction in glaucoma
inferredcites →https://doi.org/10.1136/bjo.2006.105585openalex-snapshot
The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice
inferredcites →https://doi.org/10.1136/bjophthalmol-2014-305908openalex-snapshot
A randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study
inferredcites →https://doi.org/10.1136/bjophthalmol-2016-309023openalex-snapshot
Ocular hypotensive effect of the novel EP3/FP agonist ONO-9054 versus Xalatan: results of a 28-day, double-masked, randomised study
inferredcites →https://doi.org/10.1167/iovs.05-0527openalex-snapshot
Endothelin Antagonism: Effects of FP Receptor Agonists Prostaglandin F 2α and Fluprostenol on Trabecular Meshwork Contractility
inferredcites →https://doi.org/10.1167/iovs.09-4266openalex-snapshot
Endothelial Nitric Oxide Synthase Gene Variants and Primary Open-Angle Glaucoma: Interactions with Sex and Postmenopausal Hormone Use
inferredcites →https://doi.org/10.1167/iovs.14-14515openalex-snapshot
Nitric Oxide (NO): An Emerging Target for the Treatment of Glaucoma
inferredcites →https://doi.org/10.1167/iovs.14-16015openalex-snapshot
Regulation of Endothelin-1–Induced Trabecular Meshwork Cell Contractility by Latanoprostene Bunod
inferredcites →https://doi.org/10.1167/iovs.14-16181openalex-snapshot
IOP-Lowering Effect of ONO-9054, A Novel Dual Agonist of Prostanoid EP3 and FP Receptors, in Monkeys
inferredcites →https://doi.org/10.1167/iovs.15-16564openalex-snapshot
Aqueous Humor Outflow Physiology in NOS3 Knockout Mice
inferredcites →https://doi.org/10.1167/iovs.15-17190openalex-snapshot
Intraocular Pressure–Lowering Activity of NCX 470, a Novel Nitric Oxide–Donating Bimatoprost in Preclinical Models
inferredcites →https://doi.org/10.1167/iovs.16-19585openalex-snapshot
Biocompatibility and Pharmacokinetic Analysis of an Intracameral Polycaprolactone Drug Delivery Implant for Glaucoma
inferredcites →https://doi.org/10.1167/iovs.17-22168openalex-snapshot
The Ability of Nitric Oxide to Lower Intraocular Pressure Is Dependent on Guanylyl Cyclase
inferredcites →https://doi.org/10.1248/bpb.26.1691openalex-snapshot
New Fluoroprostaglandin F2.ALPHA. Derivatives with Prostanoid FP-Receptor Agonistic Activity as Potent Ocular-Hypotensive Agents
inferredcites →https://doi.org/10.2147/opth.s103985openalex-snapshot
Critical evaluation of latanoprostene bunod in the treatment of glaucoma
inferredcites →https://doi.org/10.3109/02713683.2011.593725openalex-snapshot
A Phase 2, Randomized, Dose-Response Trial of Taprenepag Isopropyl (PF-04217329) Versus Latanoprost 0.005% in Open-Angle Glaucoma and Ocular Hypertension
inferredcites →https://doi.org/10.3389/fnmol.2014.00038openalex-snapshot
Regulation of intraocular pressure by soluble and membrane guanylate cyclases and their role in glaucoma
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4800680openalex-extracted
Rho Kinase Inhibition and Fp-Agonist Study of Rotenoids Present in Boerhavia Diffusa Root as Active Ingredient for Uveitic Glaucoma
inferred← citeshttps://doi.org/10.1002/14356007.w23_w07openalex-snapshot
Sensory Organs – Ophthalmologicals (S01)
inferred← citeshttps://doi.org/10.1002/9781119640929.ch12openalex-snapshot
Nitric Oxide, Carbon Monoxide, and Hydrogen Sulfide as Biologically Important Signaling Molecules With the Significance of Their Respective Donors in Ophthalmic Diseases
inferred← citeshttps://doi.org/10.1002/adtp.202100032openalex-snapshot
Progress and Prospects of Regulatory Functions Mediated by Nitric Oxide on Immunity and Immunotherapy
inferred← citeshttps://doi.org/10.1002/slct.202404950openalex-snapshot
In Silico Rho Kinase Inhibition and FP‐Agonist Potential Study of Rotenoids Present in Boerhavia diffusa Root for Curing Uveitic Glaucoma
inferred← citeshttps://doi.org/10.1002/wsbm.1628openalex-snapshot
Secondary glaucoma: Toward interventions based on molecular underpinnings
inferred← citeshttps://doi.org/10.1007/s40265-018-1016-1openalex-snapshot
Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval
inferred← citeshttps://doi.org/10.1016/b978-0-443-13342-8.00003-xopenalex-snapshot
Advances in the discovery of novel agents for the treatment of glaucoma: The role of nitric oxide donors
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2021.121074openalex-snapshot
Endogenous dual stimuli-activated NO generation in the conventional outflow pathway for precision glaucoma therapy
inferred← citeshttps://doi.org/10.1016/j.chroma.2024.465516openalex-snapshot
Green extraction of prostaglandin analogs in cosmetics using deep eutectic solvents and detection via LC-MS/MS
inferred← citeshttps://doi.org/10.1016/j.coph.2023.102424openalex-snapshot
Currently available prostanoids for the treatment of glaucoma and ocular hypertension: A review
inferred← citeshttps://doi.org/10.1016/j.drudis.2019.05.033openalex-snapshot
Nitric oxide: a drug target for glaucoma revisited
inferred← citeshttps://doi.org/10.1016/j.exer.2023.109415openalex-snapshot
FP and EP2 prostanoid receptor agonist drugs and aqueous humor outflow devices for treating ocular hypertension and glaucoma
inferred← citeshttps://doi.org/10.1016/j.exer.2023.109444openalex-snapshot
Identifying new drugs and targets to treat rapidly elevated intraocular pressure for angle closure and secondary glaucomas to curb visual impairment and prevent blindness
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.4c01199openalex-snapshot
Development of Nitric Oxide-Donating Netarsudil Derivatives as a Synergistic Therapy for Glaucoma with Reduced Ocular Irritation
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.5c03033openalex-snapshot
Discovery of Novel NO–Donor Containing hCA II Inhibitors with Retinal Ganglion Cell-Protective Effects for the Efficient Treatment of Glaucoma
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.9b00196openalex-snapshot
Synthetic Approaches to the New Drugs Approved During 2017
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.9b01033openalex-snapshot
Ocular Disease Therapeutics: Design and Delivery of Drugs for Diseases of the Eye
inferred← citeshttps://doi.org/10.1021/acs.jnatprod.9b01285openalex-snapshot
Natural Products as Sources of New Drugs over the Nearly Four Decades from 01/1981 to 09/2019
inferred← citeshttps://doi.org/10.1038/s41598-020-72538-xopenalex-snapshot
Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells
inferred← citeshttps://doi.org/10.1080/13543776.2019.1661992openalex-snapshot
Prostaglandin receptor agonists as antiglaucoma agents (a patent review 2013 – 2018)
inferred← citeshttps://doi.org/10.1080/13543784.2025.2472409openalex-snapshot
Investigational drugs for glaucoma: novel mechanistic approaches of preclinical agents
inferred← citeshttps://doi.org/10.1080/14728214.2022.2110240openalex-snapshot
Emerging drugs for the treatment of glaucoma: a review of phase II & III trials
inferred← citeshttps://doi.org/10.1080/14740338.2022.1996560openalex-snapshot
A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension
inferred← citeshttps://doi.org/10.1080/17460441.2021.1922384openalex-snapshot
Advances in the discovery of novel agents for the treatment of glaucoma
inferred← citeshttps://doi.org/10.1089/jop.2020.0126openalex-snapshot
NCX 1741, a Novel Nitric Oxide-Donating Phosphodiesterase-5 Inhibitor, Exerts Rapid and Long-Lasting Intraocular Pressure-Lowering in Cynomolgus Monkeys
inferred← citeshttps://doi.org/10.1097/iio.0000000000000482openalex-snapshot
New Glaucoma Medications
inferred← citeshttps://doi.org/10.1111/ceo.13814openalex-snapshot
Profiling ocular surface responses to preserved and non‐preserved topical glaucoma medications: A 2‐year randomized evaluation study
inferred← citeshttps://doi.org/10.1155/2022/3700720openalex-snapshot
Clinical Efficacy of Topical Tacrolimus on Conjunctival Hyperemia Caused by Prostaglandin Analogues
inferred← citeshttps://doi.org/10.1155/2024/9978312openalex-snapshot
Pathological Mechanism and Clinical Therapy Progress of Schlemm’s Canal
inferred← citeshttps://doi.org/10.1167/iovs.63.2.24openalex-snapshot
The Roles Played by FP/EP3 Receptors During Pressure-lowering in Mouse Eyes Mediated by a Dual FP/EP3 Receptor Agonist
inferred← citeshttps://doi.org/10.1167/tvst.10.6.27openalex-snapshot
Xeno- and Feeder-Free Differentiation of Human iPSCs to Trabecular Meshwork-Like Cells by Recombinant Cytokines
inferred← citeshttps://doi.org/10.1167/tvst.12.9.22openalex-snapshot
NCX 470 Exerts Retinal Cell Protection and Enhances Ophthalmic Artery Blood Flow After Ischemia/Reperfusion Injury of Optic Nerve Head and Retina
inferred← citeshttps://doi.org/10.1167/tvst.13.11.6openalex-snapshot
Ocular Tissue Distribution of Omidenepag Isopropyl in Rabbits and Cynomolgus Monkeys
inferred← citeshttps://doi.org/10.1177/11206721211008783openalex-snapshot
Netarsudil: A new ophthalmic drug in the treatment of chronic primary open angle glaucoma and ocular hypertension
inferred← citeshttps://doi.org/10.1177/20406223221140392openalex-snapshot
Current situation and progress of drugs for reducing intraocular pressure
inferred← citeshttps://doi.org/10.1177/20420986241285929openalex-snapshot
Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database
inferred← citeshttps://doi.org/10.1371/journal.pone.0258911openalex-snapshot
TRPV4 is activated by mechanical stimulation to induce prostaglandins release in trabecular meshwork, lowering intraocular pressure
inferred← citeshttps://doi.org/10.1371/journal.pone.0315010openalex-snapshot
Adult male-specific inverse association between dry eye disease and intraocular pressure: KNHANES 2010–2012
inferred← citeshttps://doi.org/10.1515/revic-2021-0009openalex-snapshot
NO, CO and H2S based pharmaceuticals in the mission of vision (eye health): a comprehensive review
inferred← citeshttps://doi.org/10.20944/preprints202305.0309.v1openalex-snapshot
NCX 470, a Dual Acting Nitric Oxide (NO)-Donating Bimatoprost Derivative, Preserves Rabbit Eyes from Biochemical and Functional Changes Associated with ET-1-Induced Ischemia/Reperfusion Injury
inferred← citeshttps://doi.org/10.2147/opth.s340386openalex-snapshot
Efficacy and Patient Tolerability of Omidenepag Isopropyl in the Treatment of Glaucoma and Ocular Hypertension
inferred← citeshttps://doi.org/10.22541/au.160614188.83707688/v1openalex-snapshot
The primary gasotransmitters and their respective donors in the mission of vision (eye health): a comprehensive overview
inferred← citeshttps://doi.org/10.30737/jafi.v6i1.6240openalex-snapshot
Profil dan Efektivitas Terapi pada Pasien Glaukoma Rawat Jalan di RSUD Daha Husada Kediri
inferred← citeshttps://doi.org/10.3389/fmed.2021.733080openalex-snapshot
Glaucoma Clinical Research: Trends in Treatment Strategies and Drug Development
inferred← citeshttps://doi.org/10.3389/fphar.2021.749858openalex-snapshot
Topical Medication Therapy for Glaucoma and Ocular Hypertension
inferred← citeshttps://doi.org/10.3390/biomedicines11112959openalex-snapshot
Therapeutic Potential of Antioxidants and Hybrid TEMPOL Derivatives in Ocular Neurodegenerative Diseases: A Glimpse into the Future
inferred← citeshttps://doi.org/10.3390/biomedicines9080930openalex-snapshot
Screening of the Drug-Induced Effects of Prostaglandin EP2 and FP Agonists on 3D Cultures of Dexamethasone-Treated Human Trabecular Meshwork Cells
inferred← citeshttps://doi.org/10.3390/ijms241713211openalex-snapshot
The Association between Vascular Abnormalities and Glaucoma—What Comes First?
inferred← citeshttps://doi.org/10.3390/jcm11061652openalex-snapshot
Comparison of the Drug-Induced Efficacies between Omidenepag Isopropyl, an EP2 Agonist and PGF2α toward TGF-β2-Modulated Human Trabecular Meshwork (HTM) Cells
inferred← citeshttps://doi.org/10.3390/molecules26237306openalex-snapshot
The Application of Nitric Oxide for Ocular Hypertension Treatment
inferred← citeshttps://doi.org/10.3390/ph16030339openalex-snapshot
Asymmetric Synthesis of US-FDA Approved Drugs over Five Years (2016–2020): A Recapitulation of Chirality
inferred← citeshttps://doi.org/10.3390/ph17050561openalex-snapshot
From Eye Care to Hair Growth: Bimatoprost
inferred← citeshttps://doi.org/10.4103/ijo.ijo_2387_25openalex-snapshot
Prostaglandin analog therapy challenges and innovation in glaucoma therapeutics
inferred← citeshttps://doi.org/10.4314/tjpr.v23i1.27openalex-snapshot
Glaucoma: A review of current management, patients’ adherence, direct and indirect cost, and barriers to drug delivery
inferred← citeshttps://doi.org/10.5772/intechopen.1013213openalex-snapshot
Newer Medical Management Options in Glaucoma
inferred← citeshttps://doi.org/10.6061/clinics/2020/e1874openalex-snapshot
Comparative evaluation of Latanoprostene Bunod, Timolol Maleate, and latanoprost Ophthalmic Solutions to assess their safety and efficacy in lowering intraocular pressure for the management of Open-Angle Glaucoma
showing the first 60 of 61 · page through all 61
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.